Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITAL: Carboplatin plus nab-paclitaxel vs docetaxel in elderly squamous NSCLC
jRCTs041180110Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial in Pulmonary squamous cell carcinoma comparing Docetaxel with Carboplatin plus nab-paclitaxel (2 arms). Primary endpoint: Overall survival. Started Feb 2016; status: completed.
02
Drugs
docetaxelcarboplatinpaclitaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCTs041180110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180110.